Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Temedica

Request full access

Health insights ecosystem for real-world evidence

Munich, GermanyFounded 2016Biotech & Life Sciences

About Temedica

Temedica is a digital health company founded in 2016 in Munich, Germany, by Gloria Seibert and Benjamin Friedrich. Gloria Seibert, the CEO, was motivated to start the company due to her grandfather's battle with multiple sclerosis, which highlighted the need for more personalized patient support. Before Temedica, she worked as a business consultant at McKinsey and studied software engineering in Silicon Valley to gain the necessary technological expertise. Co-founder and Chief Medical Officer, PD Dr. med Benjamin Friedrich, brings extensive medical and academic experience from his work in radiology and neuroradiology at institutions like the Technical University of Munich.

The company operates a health insights ecosystem designed to centralize and analyze health data from various sources to generate real-world evidence. This ecosystem serves a wide range of clients, including pharmaceutical companies, research institutions, healthcare professionals, and patients. Temedica's business model is centered on partnerships with pharmaceutical firms, providing them with anonymized, GDPR-compliant data that offers insights into disease progression, patient journeys, and treatment effectiveness outside of traditional clinical trials. Partners have included major companies like Roche and AbbVie Germany.

Temedica's core offerings include digital patient companion apps and the Permea real-world insights platform. The companion apps are designed for patients with chronic conditions such as multiple sclerosis, psoriasis, and cancer, offering personalized guidance and support. The Permea platform integrates patient-generated data from these apps with other sources like registry and insurance data to provide a comprehensive view of patient care realities. This allows clients to receive customized analytics and reports that inform strategic decisions in areas like product development, market strategy, and patient engagement. The company has raised a total of $44.6 million in funding, including a Series B round that closed in November 2022.

Source: Dealroom company data

At a glance

Status
Operational
Employees
67
Open positions
3
Dealroom signal
70.6/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Clinical, Remote Monitoring, Core AI, Digital Therapeutics
Technology
Artificial Intelligence, Deep Tech, Machine Learning, Natural Language Processing
Business model
SaaS
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Nov 2022 $28M $110M MIG Capital ↗
SERIES A✓Equity / VC Jan 2020 $19M $75M G+J Ventures · MIG Capital · Bernd Wendeln · Santo Venture Capital ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Temedica website traffic

Latest recorded traffic for Temedica is 5.4K monthly website visits, down 19.4% over the last three months. Temedica's team declined 6.9% over the past year.

Latest monthly visits5.4K 3-month web change-19.4% 1-year team growth-6.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Temedica in the Munich ecosystem

Live from Dealroom

The Temedica office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • G+J Ventures
  • MIG Capital
  • Bernd Wendeln
  • Santo Venture Capital

Other known investors2 additional known investors

  • Christophe Aumaître
  • WENVEST Capital
Team profiled 19 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See Temedica’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.